Deutsche Bank Has Buy On Auxilium Pharmaceuticals (AUXL)

Deutsche Bank has a Buy rating and a $28 price target on shares of Auxilium Pharmaceuticals AUXL. In a note to cliens, Deutsche Bank writes, "We recently hosted a series of investor meetings with management in California. Following these meetings, we maintain our Buy rating and continue to believe that AUXL shares look attractive. Our rating is predicated on the significant commercial opportunity for Xiaflex, coupled with a still solid growth outlook for Testim. We believe that Xiaflex, the company's potential flagship, non-surgical treatment for Dupuytren's contracture, could have peak sales potential of $400M+ in the US." Shares of AUXL lost 11 cents yesterday to close at $21.19, a loss of 0.5%.